Corrigendum: Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats (International Journal of Neuropsychopharmacology (2010) DOI: 10.1017/S146114570999023X);Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats

International Journal of Neuropsychopharmacology

Volumn 13, Issue 3, 2010, Pages 373-386

  Seillier, Alexandre ^a   Advani, Tushar ^a   Cassano, TOMMASO ^b   Hensler, Julie G ^a   Giuffrida, Andrea ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Cannabinoid; Motor activity; Schizophrenia; Social interaction; Working memory

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; ENZYME INHIBITION; HYPERACTIVITY; MALE; MEMORY DISORDER; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; VENTRAL TEGMENTUM; WORKING MEMORY;

EID: 77952882862     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyx039     Document Type: Erratum

References (65)

1. Andersson M, Terasmaa A, Fuxe K, Stromberg I (2005). Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia. Journal of Neuroscience Research 82, 264-272.
2. Arseneault L, Cannon M, Poulton R, Murray R, et al. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 325, 1212-1213.
3. Auclair N, Otani S, Soubrie P, Crepel F (2000). Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. Journal of Neurophysiology 83, 3287-3293.
4. Aultman JM, Moghaddam B (2001). Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology (Berlin) 153, 353-364.
5. Collins CM, Kalinichev M, Southam E, Wood M, Elliott JM (2006). Effect of subchronic phencyclidine pretreatment on amphetamine induced locomotor activity and Arc mRNA expression in hooded Wistar rats: comparison with Sprague Dawley rats. Society for Neuroscience Annual Meeting. Abstract 688.3.
6. Corbille AG, Valjent E, Marsicano G, Ledent C, et al. (2007). Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. Journal of Neuroscience 27, 6937-6947.
7. D'Souza DC (2007). Cannabinoids and psychosis. International Revue of Neurobiology 78, 289-326.
8. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594-608.
9. D'Souza DC, Perry E, MacDougall L, Ammerman Y, et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558-1572.
10. De Lago E, Petrosino S, Valenti M, Morera E, et al. (2005). Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochemical Pharmacology 70, 446-452.
11. De Marchi N, De Petrocellis L, Orlando P, Daniele F, et al. (2003). Endocannabinoid signaling in the blood of patients with schizophrenia. Lipids in Health and Disease 2, 5.
12. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15.
13. Delatour B, Gisquet-Verrier P (1999). Lesions of the prelimbic- infralimbic cortices in rats do not disrupt response selection processes but induce delay-dependent deficits: evidence for a role in working memory? Behavioral Neuroscience 113, 941-955.
14. Egerton A, Allison C, Brett RR, Pratt JA (2006). Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neuroscience and Biobehavioral Reviews 30, 680-695.
15. Egerton A, Reid L, McGregor S, Cochran SM, et al. (2008). Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology (Berlin) 198, 37-49.
16. Emrich HM, Leweke FM, Schneider U (1997). Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacology Biochemistry and Behavior 56, 803-807.
17. Enomoto T, Noda Y, Nabeshima T (2007). Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods and Findings in Experimental and Clinical Pharmacology 29, 291-301.
18. Fattore L, Vigano D, Fadda P, Rubino T, et al. (2007). Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. European Journal of Neuroscience 25, 2191-2200.
19. Fegley D, Gaetani S, Duranti A, Tontini A, et al. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. Journal of Pharmacology and Experimental Therapeutics 313, 352-358.
20. Floresco SB, Tse MT (2007). Dopaminergic regulation of inhibitory and excitatory transmission in the basolateral amygdala-prefrontal cortical pathway. Journal of Neuroscience 27, 2045-2057.
21. Geary WA, Wooten GF (1983). Quantitative film autoradiography of opiate agonist and antagonist binding in rat brain. Journal of Pharmacology and Experimental Therapeutics 225, 234-240.
22. 3H]naloxone binding in the naive, dependent and withdrawal states. Brain Research 360, 214-223.
23. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, et al. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114.
24. Giuffrida A, Parsons LH, Kerr TM, Rodriguez DF, et al. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience 2, 358-363.
25. Hardison S, Weintraub ST, Giuffrida A (2006). Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. Prostaglandins & Other Lipid Mediators 81, 106-112.
26. Hill MN, Karacabeyli ES, Gorzalka BB (2007). Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 32, 350-357.
27. Houchi H, Babovic D, Pierrefiche O, Ledent C, et al. (2005). CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30, 339-349.
28. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, et al. (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. British Journal of Pharmacology 147, 281-288.
29. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225.
30. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17, 92-99.
31. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, et al. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences USA 93, 9235-9240.
32. Laruelle M, Kegeles LS, Abi-Dargham A (2003). Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Annals of the New York Academy of Sciences 1003, 138-158.
33. Laviolette SR, Grace AA (2006). Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs. Journal of Neuroscience 26, 6458-6468.
34. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI (2005). Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30, 1883-1894.
35. Leweke FM, Giuffrida A, Koethe D, Schreiber D, et al. (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research 94, 29-36.
36. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999). Elevated endogenous cannabinoids in schizophrenia. NeuroReport 10, 1665-1669.
37. Maccarrone M, Rossi S, Bari M, De Chiara V, et al. (2008). Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nature Neuroscience 11, 152-159.
38. Malone DT, Kearn CS, Chongue L, Mackie K, Taylor DA (2007). Effect of social isolation on CB(1) and D(2) receptor and fatty acid amide hydrolase expression in rats. Neuroscience 152, 265-272.
39. Manoach DS (2003). Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophrenia Research 60, 285-298.
40. Marquis JP, Audet MC, Dore FY, Goulet S (2007). Delayed alternation performance following subchronic phencyclidine administration in rats depends on task parameters. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 1108-1112.
41. Masserano JM, Karoum F, Wyatt RJ (1999). SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behavioural Pharmacology 10, 429-432.
42. Melis M, Perra S, Muntoni AL, Pillolla G, et al. (2004). Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. Journal of Neuroscience 24, 10707-10715.
43. Moise AM, Eisenstein SA, Astarita G, Piomelli D, Hohmann AG (2008). An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berlin) 200, 333-346.
44. Morgese MG, Cassano T, Cuomo V, Giuffrida A (2007). Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Experimental Neurology 208, 110-119.
45. Morris BJ, Cochran SM, Pratt JA (2005). PCP: from pharmacology to modeling schizophrenia. Current Opinion in Pharmacology 5, 101-106.
46. Murphy BL, Arnsten AF, Goldman-Rakic PS, Roth RH (1996). Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proceedings of the National Academy of Sciences USA 93, 1325-1329.
47. Newell KA, Deng C, Huang XF (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research 172, 556-560.
48. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates, 4th edn. New York: Academic Press.
49. Piomelli D (2003). The molecular logic of endocannabinoid signaling. Nature Reviews Neuroscience 4, 873-884.
50. Pryor SR (2000). Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal. Medical Hypotheses 55, 494-501.
51. Qiao H, Noda Y, Kamei H, Nagai T, et al. (2001). Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. NeuroReport 12, 11-15.
52. Sams-Dodd F (1998a). Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19, 18-25.
53. Sams-Dodd F (1998b). Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neuroscience and Biobehavioral Reviews 23, 287-293. (Pubitemid 29011631)
54. Seillier A, Giuffrida A (2009). Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behavioural Brain Research. Published online: 14 February 2009. doi:10.1016/j.bbr.2009.02.007.
55. Sim-Selley LJ, Martin BR (2002). Effect of chronic administration of R-(¡)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de] -1,4-b enzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. Journal of Pharmacology and Experimental Therapeutics 303, 36-44.
56. Snigdha S, Neill JC (2008). Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behavioural Brain Research 191, 26-31.
57. Solinas M, Justinova Z, Goldberg SR, Tanda G (2006). Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. Journal of Neurochemistry 98, 408-419.
58. Stevenson CW, Gratton A (2003). Basolateral amygdala modulation of the nucleus accumbens dopamine response to stress: role of the medial prefrontal cortex. European Journal of Neuroscience 17, 1287-1295. (Pubitemid 36459783)
59. Stevenson CW, Sullivan RM, Gratton A (2003). Effects of basolateral amygdala dopamine depletion on the nucleus accumbens and medial prefrontal cortical dopamine responses to stress. Neuroscience 116, 285-293. (Pubitemid 36110453)
60. Thiemann G, Di Marzo V, Molleman A, Hasenohrl RU (2008a). The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacology, Biochemistry and Behavior 89, 384-391.
61. Thiemann G, van der Stelt M, Petrosino S, Molleman A, et al. (2008b). The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behavioural Brain Research 187, 289-296.
62. Trezza V, Vanderschuren LJ (2007). Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (Berlin) 197, 217-227.
63. Ujike H, Takaki M, Nakata K, Tanaka Y, et al. (2002). CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Molecular Psychiatry 7, 515-518.
64. Vigano D, Guidali C, Petrosino S, Realini N, et al. (2008). Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modeling schizophrenia. International Journal of Neuropsychopharmacology 15, 1-16.
65. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro- Psychopharmacology and Biological Psychiatry 28, 355-360.